{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T21:05:40Z","timestamp":1790888740459,"version":"4.1.0"},"reference-count":5,"publisher":"Oxford University Press (OUP)","issue":"10","license":[{"start":{"date-parts":[[2022,8,3]],"date-time":"2022-08-03T00:00:00Z","timestamp":1659484800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"NanoCarrier Co., Ltd."}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,10,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>NC-6300 is a novel epirubicin (EPI) drug conjugated polymeric micelle developed using cutting-edge micellar nanoparticle technology. The nanoparticle epirubicin conjugates EPI to a polymer via a pH-sensitive linker which enables the selective EPI release into tumor. Tumor activity was observed in a monotherapy phase Ib trial, where two of two patients with angiosarcoma achieved a partial response. To further explore the activity of NC-6300 in angiosarcoma, an expansion cohort was undertaken.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Ten patients with angiosarcoma were enrolled in the expansion cohort. Patients were dosed using the recommended dose of 150 mg\/m2 intravenously (IV) once every 3 weeks. The primary endpoint was progression-free survival.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>The most common adverse events (AEs) of any grade, regardless of the causal relationship with NC-6300, were neutropenia (90%), fatigue, and thrombocytopenia (60% each) and nausea (50%). The most common grades 3 and 4 AEs were neutropenia (80%), thrombocytopenia (40%), and anemia and leukopenia (20% each). The median progression-free survival (mPFS) for all subjects was 5.4 months. The mPFS was 3.8 months in subjects with prior anthracycline treatment and 8.2 months in subjects without prior anthracycline treatment.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>NC-6300 was well tolerated, showing promising activity in angiosarcoma patients without prior anthracycline treatment. NC-6300 warrants further investigation (ClinicalTrials.gov Identifier: NCT03168061).<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/oncolo\/oyac155","type":"journal-article","created":{"date-parts":[[2022,8,3]],"date-time":"2022-08-03T14:40:37Z","timestamp":1659537637000},"page":"809-e765","source":"Crossref","is-referenced-by-count":21,"title":["Results of NC-6300 (Nanoparticle Epirubicin) in an Expansion Cohort of Patients with Angiosarcoma"],"prefix":"10.1093","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5412-8710","authenticated-orcid":false,"given":"Richard F","family":"Riedel","sequence":"first","affiliation":[{"name":"Duke Cancer Institute, Duke University Medical Center , Durham, NC , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victoria","family":"Chua","sequence":"additional","affiliation":[{"name":"Sarcoma Oncology Research Center , Santa Monica, CA , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ania","family":"Moradkhani","sequence":"additional","affiliation":[{"name":"Sarcoma Oncology Research Center , Santa Monica, CA , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalie","family":"Krkyan","sequence":"additional","affiliation":[{"name":"Sarcoma Oncology Research Center , Santa Monica, CA , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amir","family":"Ahari","sequence":"additional","affiliation":[{"name":"Sarcoma Oncology Research Center , Santa Monica, CA , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atsushi","family":"Osada","sequence":"additional","affiliation":[{"name":"NanoCarrier Co., Ltd. , Tokyo , Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sant P","family":"Chawla","sequence":"additional","affiliation":[{"name":"Sarcoma Oncology Research Center , Santa Monica, CA , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2022,8,3]]},"reference":[{"issue":"32","key":"2022100119173226200_CIT0001","doi-asserted-by":"crossref","first-page":"5269","DOI":"10.1200\/JCO.2008.17.3146","article-title":"Phase II trial of weekly paclitaxel for unresectable angiosarcoma: the ANGIOTAX Study","volume":"26","author":"Penel","year":"2008","journal-title":"J Clin Oncol"},{"issue":"12","key":"2022100119173226200_CIT0002","doi-asserted-by":"crossref","first-page":"1634","DOI":"10.1038\/bjc.1998.735","article-title":"High-dose epirubicin is not an alternative to standard-dose doxorubicin in the treatment of advanced soft tissue sarcomas. A study of the EORTC soft tissue and bone sarcoma group","volume":"78","author":"Nielsen","year":"1998","journal-title":"Br J Cancer"},{"issue":"4","key":"2022100119173226200_CIT0003","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.4143\/crt.2020.1337","article-title":"Real-world clinical outcomes and prognostic factors for patients with advanced angiosarcoma who received systemic treatment","volume":"53","author":"Park","year":"2021","journal-title":"Cancer Res Treat"},{"issue":"18","key":"2022100119173226200_CIT0004","doi-asserted-by":"crossref","first-page":"3178","DOI":"10.1016\/j.ejca.2014.10.004","article-title":"First-line anthracycline-based chemotherapy for angiosarcoma and other soft tissue sarcoma subtypes: Pooled analysis of eleven European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group trials","volume":"50","author":"Young","year":"2014","journal-title":"Eur J Cancer"},{"issue":"4","key":"2022100119173226200_CIT0005","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1159\/000381917","article-title":"Outcomes of systemic therapy for patients with metastatic angiosarcoma","volume":"89","author":"D\u2019Angelo","year":"2015","journal-title":"Oncology"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/27\/10\/809\/46284910\/oyac155.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/27\/10\/809\/46284910\/oyac155.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T19:18:14Z","timestamp":1664651894000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/27\/10\/809\/6654611"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,3]]},"references-count":5,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2022,8,3]]},"published-print":{"date-parts":[[2022,10,1]]}},"URL":"https:\/\/doi.org\/10.1093\/oncolo\/oyac155","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2022,10,1]]},"published":{"date-parts":[[2022,8,3]]}}}